secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001437749-25-032658
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics raises BRIUMVI revenue guidance to $585M, Q3 net income $390.9M
-------------------------------------------------------------------------------

- Q3 2025 total revenue $161.7M, BRIUMVI US net revenue $152.9M up 84% YoY.
- Raises FY2025 BRIUMVI US net revenue target to ~$585M (prior $570-575M) and global target to $600M.
- Q3 net income $390.9M includes $365M non-recurring tax benefit; net income $3.9M in Q3 2024.
- Completed $100M buyback (3.5M shares at avg $28.55); authorized new $100M repurchase program.
- Phase 3 subcutaneous ublituximab enrollment commenced; ENHANCE trial for consolidated IV dosing fully enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774925032658/0001437749-25-032658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774925032658/tgtx20250909_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-032658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer